Lista de obras - Guillermo Izquierdo - Dominio Público Uruguay

A New Risk Variant for Multiple Sclerosis at 11q23.3 Locus Is Associated with Expansion of CXCR5+ Circulating Regulatory T Cells

artículo científico publicado en 2020

A functional variant that affects exon-skipping and protein expression of SP140 as genetic mechanism predisposing to multiple sclerosis.

artículo científico publicado en 2015

A new risk variant for multiple sclerosis at the immunoglobulin heavy chain locus associates with intrathecal IgG, IgM index and oligoclonal bands

artículo científico publicado en 2014

A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe

artículo científico publicado en 2014

A study of promoter and intronic markers of ApoI/Fas gene and the interaction with Fas ligand in relapsing multiple sclerosis

artículo científico publicado en 2004

Adherence to interferon β-1b treatment in patients with multiple sclerosis in Spain

artículo científico publicado en 2012

Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study.

artículo científico publicado en 2018

Altered individual behavioral and EEG parameters are related to the EDSS score in relapsing-remitting multiple sclerosis patients

scientific article published on 15 July 2019

Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients

artículo científico publicado en 2016

Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.

artículo científico publicado en 2017

Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis

artículo científico publicado en 2008

Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis

artículo científico publicado en 2018

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

scientific article published on 01 January 2019

Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis

scientific article published on 27 July 2020

Biomarkers in multiple sclerosis

artículo científico publicado en 2013

Biomarkers in multiple sclerosis: an update for 2014

artículo científico publicado en 2014

Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder

artículo científico publicado en 2019

Clinical case reviews and poster sessions in multiple sclerosis spasticity: main outcomes and highlights.

artículo científico publicado en 2014

Closing the case ofAPOEin multiple sclerosis: no association with disease risk in over 29 000 subjects: Figure 1

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

artículo científico publicado en 2014

Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.

artículo científico publicado en 2016

Comparative efficacy of switching to natalizumab in active multiple sclerosis

artículo científico publicado en 2015

Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis

scientific article published on 13 January 2019

Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study

scientific article published on 01 July 2020

Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis

artículo científico publicado en 2015

Contribution of different relapse phenotypes to disability in multiple sclerosis.

artículo científico publicado en 2016

Correction: Adherence to Interferon β-1b Treatment in Patients with Multiple Sclerosis in Spain.

artículo científico publicado en 2012

Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome

artículo científico publicado en 2012

Defining reliable disability outcomes in multiple sclerosis.

artículo científico publicado en 2015

Defining secondary progressive multiple sclerosis

artículo científico publicado en 2016

Delay from treatment start to full effect of immunotherapies for multiple sclerosis

scientific article published on 01 September 2020

Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis

artículo científico publicado en 2020

Disentangling the attention network test: behavioral, event related potentials, and neural source analyses.

artículo científico publicado en 2014

Dynamic regulation of serum aryl hydrocarbon receptor agonists in MS

artículo científico publicado en 2017

Early clinical markers of aggressive multiple sclerosis

scientific article published on 09 May 2020

Effect of Disease Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years

scientific article published on 28 December 2020

Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS

scientific article published on 06 January 2021

Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies

artículo científico publicado en 2019

Evaluation of More Stamina, a Mobile App for Fatigue Management in Persons with Multiple Sclerosis: Protocol for a Feasibility, Acceptability, and Usability Study

artículo científico publicado en 2020

Exome sequencing in multiple sclerosis families identifies 12 candidate genes and nominates biological pathways for the genesis of disease

artículo científico publicado en 2019

Fingolimod after natalizumab and the risk of short-term relapse

artículo científico publicado en 2014

Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.

artículo científico publicado en 2013

Genome-wide association study of multiple sclerosis confirms a novel locus at 5p13.1

artículo científico publicado en 2012

Genome-wide significant association with seven novel multiple sclerosis risk loci

artículo científico publicado en 2015

Geographical variations in sex ratio trends over time in multiple sclerosis.

artículo científico publicado en 2012

HERV-W polymorphism in chromosome X is associated with multiple sclerosis risk and with differential expression of MSRV.

artículo científico publicado en 2014

Hexose-6-phosphate dehydrogenase: a new risk gene for multiple sclerosis

artículo científico publicado en 2009

Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.

artículo científico publicado en 2016

Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis

artículo científico publicado en 2016

Human endogenous retrovirus HERV-Fc1 association with multiple sclerosis susceptibility: a meta-analysis

artículo científico publicado en 2014

IL2RA/CD25 gene polymorphisms: uneven association with multiple sclerosis (MS) and type 1 diabetes (T1D).

artículo científico publicado en 2009

Identification of a functional variant in the KIF5A-CYP27B1-METTL1-FAM119B locus associated with multiple sclerosis

artículo científico publicado en 2012

Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis.

artículo científico publicado en 2014

Immunological markers of optimal response to natalizumab in multiple sclerosis.

artículo científico publicado en 2012

Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study

scientific article published on 03 January 2019

Increasing age at disability milestones among MS patients in the MSBase Registry

artículo científico

Influence of the LILRA3 Deletion on Multiple Sclerosis Risk: Original Data and Meta-Analysis.

artículo científico publicado en 2015

Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab

artículo científico publicado en 2015

Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis

artículo científico publicado en 2017

Long-term epidemiology of multiple sclerosis in the Northern Seville District

artículo científico publicado en 2015

Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab

scientific article published on 29 October 2019

MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis

artículo científico publicado en 2013

Magnetic resonance spectroscopy of normal appearing white matter in early relapsing-remitting multiple sclerosis: correlations between disability and spectroscopy

artículo científico publicado en 2004

Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS

artículo científico publicado en 2015

Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry

artículo científico publicado en 2015

Multiple sclerosis risk variant HLA-DRB1*1501 associates with high expression of DRB1 gene in different human populations

artículo científico publicado en 2012

Mutation prevalence of cerebral cavernous malformation genes in Spanish patients

artículo científico publicado en 2014

Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles.

artículo científico publicado en 2014

Neural correlates of alerting and orienting impairment in multiple sclerosis patients.

artículo científico publicado en 2014

New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab

scientific article published on 17 December 2020

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

artículo científico publicado en 2010

Perception of stigma in patients with primary progressive multiple sclerosis

scientific article published on 01 April 2019

Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis

artículo científico publicado en 2013

Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score

artículo científico publicado en 2020

Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab

artículo científico publicado en 2020

Predictors and dynamics of postpartum relapses in women with multiple sclerosis.

artículo científico publicado en 2013

Predictors of disability worsening in clinically isolated syndrome.

artículo científico publicado en 2015

Predictors of long-term disability accrual in relapse-onset multiple sclerosis

artículo científico publicado en 2016

Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy

Prognostic indicators in pediatric clinically isolated syndrome

artículo científico publicado en 2017

Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies

artículo científico publicado en 2020

Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice.

artículo científico publicado en 2016

Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis

artículo científico publicado en 2015

Regulation by interferon beta-1a of reactive oxygen metabolites production by lymphocytes and monocytes and serum sulfhydryls in relapsing multiple sclerosis patients

artículo científico publicado en 2003

Replication study of 10 genes showing evidence for association with multiple sclerosis: validation of TMEM39A, IL12B and CLBL genes

article

Retest reliability of individual p3 topography assessed by high density electroencephalography

artículo científico publicado en 2013

Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I).

artículo científico

Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II).

artículo científico

Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I).

artículo científico publicado en 2013

Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III).

artículo científico publicado en 2013

Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II)

artículo científico

Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III).

artículo científico publicado en 2014

Risk of relapse phenotype recurrence in multiple sclerosis.

artículo científico publicado en 2014

Risk of secondary progressive multiple sclerosis: A longitudinal study

scientific article published on 09 August 2019

Seasonal variation of relapse rate in multiple sclerosis is latitude dependent.

artículo científico publicado en 2014

Serum antibodies to phosphatidylcholine in MS

artículo científico publicado en 2020

Sex as a determinant of relapse incidence and progressive course of multiple sclerosis

artículo científico publicado en 2013

Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis

scientific article published on 20 September 2018

Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD)

artículo científico publicado en 2019

Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study

scientific article published on 02 April 2020

Splice-site variant in ACSL5: a marker promoting opposing effect on cell viability and protein expression

scientific article published on 03 May 2019

Study of cerebral cavernous malformation in Spain and Portugal: high prevalence of a 14 bp deletion in exon 5 of MGC4607 (CCM2 gene).

artículo científico publicado en 2007

Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort.

artículo científico publicado en 2016

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.

artículo científico publicado en 2015

TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis.

artículo científico publicado en 2013

Tag-SNP analysis of the GFI1-EVI5-RPL5-FAM69 risk locus for multiple sclerosis

artículo científico publicado en 2010

Targeted resequencing reveals rare variants enrichment in multiple sclerosis susceptibility genes

artículo científico publicado en 2020

The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

artículo científico publicado en 2015

The high producer variant of the Fc-receptor like-3 (FCRL3) gene is involved in protection against multiple sclerosis

artículo científico publicado en 2008

The multiple sclerosis-associated regulatory variant rs10877013 affects expression of CYP27B1 and VDR under inflammatory or vitamin D stimuli.

artículo científico publicado en 2015

The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study.

artículo científico publicado en 2017

Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study

artículo científico publicado en 2020

Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE.

artículo científico publicado en 2009

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.

artículo científico publicado en 2017

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.

artículo científico publicado en 2017

Treatment response score to glatiramer acetate or interferon beta-1a

artículo científico publicado en 2020

Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor

artículo científico publicado en 2016

[Review of the novelties presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I)]

artículo científico publicado en 2011

Lista de obras de Guillermo Izquierdo

A New Risk Variant for Multiple Sclerosis at 11q23.3 Locus Is Associated with Expansion of CXCR5+ Circulating Regulatory T Cells

A functional variant that affects exon-skipping and protein expression of SP140 as genetic mechanism predisposing to multiple sclerosis.

A new risk variant for multiple sclerosis at the immunoglobulin heavy chain locus associates with intrathecal IgG, IgM index and oligoclonal bands

A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe

A study of promoter and intronic markers of ApoI/Fas gene and the interaction with Fas ligand in relapsing multiple sclerosis

Adherence to interferon β-1b treatment in patients with multiple sclerosis in Spain

Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study.

Altered individual behavioral and EEG parameters are related to the EDSS score in relapsing-remitting multiple sclerosis patients

Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients

Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.

Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis

Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis

Biomarkers in multiple sclerosis

Biomarkers in multiple sclerosis: an update for 2014

Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder

Clinical case reviews and poster sessions in multiple sclerosis spasticity: main outcomes and highlights.

Closing the case ofAPOEin multiple sclerosis: no association with disease risk in over 29 000 subjects: Figure 1

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.

Comparative efficacy of switching to natalizumab in active multiple sclerosis

Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis

Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study

Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis

Contribution of different relapse phenotypes to disability in multiple sclerosis.

Correction: Adherence to Interferon β-1b Treatment in Patients with Multiple Sclerosis in Spain.

Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome

Defining reliable disability outcomes in multiple sclerosis.

Defining secondary progressive multiple sclerosis

Delay from treatment start to full effect of immunotherapies for multiple sclerosis

Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis

Disentangling the attention network test: behavioral, event related potentials, and neural source analyses.

Dynamic regulation of serum aryl hydrocarbon receptor agonists in MS

Early clinical markers of aggressive multiple sclerosis

Effect of Disease Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years

Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS

Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies

Evaluation of More Stamina, a Mobile App for Fatigue Management in Persons with Multiple Sclerosis: Protocol for a Feasibility, Acceptability, and Usability Study

Exome sequencing in multiple sclerosis families identifies 12 candidate genes and nominates biological pathways for the genesis of disease

Fingolimod after natalizumab and the risk of short-term relapse

Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.

Genome-wide association study of multiple sclerosis confirms a novel locus at 5p13.1

Genome-wide significant association with seven novel multiple sclerosis risk loci

Geographical variations in sex ratio trends over time in multiple sclerosis.

HERV-W polymorphism in chromosome X is associated with multiple sclerosis risk and with differential expression of MSRV.

Hexose-6-phosphate dehydrogenase: a new risk gene for multiple sclerosis

Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.

Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis

Human endogenous retrovirus HERV-Fc1 association with multiple sclerosis susceptibility: a meta-analysis

IL2RA/CD25 gene polymorphisms: uneven association with multiple sclerosis (MS) and type 1 diabetes (T1D).

Identification of a functional variant in the KIF5A-CYP27B1-METTL1-FAM119B locus associated with multiple sclerosis

Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis.

Immunological markers of optimal response to natalizumab in multiple sclerosis.

Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study

Increasing age at disability milestones among MS patients in the MSBase Registry

Influence of the LILRA3 Deletion on Multiple Sclerosis Risk: Original Data and Meta-Analysis.

Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab

Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis

Long-term epidemiology of multiple sclerosis in the Northern Seville District

Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab

MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis

Magnetic resonance spectroscopy of normal appearing white matter in early relapsing-remitting multiple sclerosis: correlations between disability and spectroscopy

Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS

Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry

Multiple sclerosis risk variant HLA-DRB1*1501 associates with high expression of DRB1 gene in different human populations

Mutation prevalence of cerebral cavernous malformation genes in Spanish patients

Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles.

Neural correlates of alerting and orienting impairment in multiple sclerosis patients.

New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

Perception of stigma in patients with primary progressive multiple sclerosis

Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis

Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score

Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab

Predictors and dynamics of postpartum relapses in women with multiple sclerosis.

Predictors of disability worsening in clinically isolated syndrome.

Predictors of long-term disability accrual in relapse-onset multiple sclerosis

Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy